SPEAKERS IN ALPHABETICAL ORDER

GEORGIA BEASLEY, MD Dr. Georgia Beasley is an assistant professor of surgery in the division of Surgical Oncology at Duke University. She obtained her undergraduate degree from Duke University while also being selected a two-me Atlanc Coast Conference Player of the Year and Two-Time All-American for the Duke University varsity women’s basketball team. Aer playing 3 years in the women’s NBA, she returned to medical school. She obtained her MD (2008) and Masters of Health Science in clinical research (2010) from Duke University School of Medicine. She then completed general surgical residency at Duke University which she completed in 2015, during which me she was awarded a traineeship under a long-standing Surgical Oncology T32 grant and played a significant role in the preclinical development, trial design, trial accrual, and analysis for mulple Phase I and II clinical trials developing novel therapeucs in melanoma. She recently completed a fellowship in complex surgical oncology at the Ohio State University. She returned to Duke in 2019 as a faculty member and is currently the co-director of the Duke Melanoma Program. She has first authored over 60 publicaons mostly centered on the treatment of melanoma. She is principal invesgator of several therapeuc clinical trials in melanoma along with translaonal projects. Her main clinical and research interests include immunologic aspects of melanoma including oncolyc viral therapy. Most recently she has received the Society of Surgical Oncology’s Young Invesgator Award to study tumor draining lymph nodes in melanoma and was recently named to Duke Medical School’s Alpha Omega Alpha, the medical honor society.

STEPHANIE GOFF, MD: Dr. Stephanie Goff is a surgeon on the senior staff of the Surgery Branch of the Naonal Cancer Instute at the NIH. Her research interests include adopve cell therapy for the treatment of solid tumors, building on the backbone of success in paents with metastac melanoma to invesgate the strategy in paents with metastac breast cancer. Her publicaons range from analysis of early trials of checkpoint blockade to genec modificaons of T-cell receptors. She was a featured physician in the Discovery Channel film, “First in Human”, documenng life at the NIH’s Clinical Center in Bethesda, MD.

She is an honors graduate of the Georgia Instute of Technology (Mechanical Engineering) and obtained her MD at the University of South Florida in Tampa. Aer training in tumor immunology under Dr. Steven Rosenberg, Dr. Goff completed her general surgery residency at Columbia University followed by a surgical oncology fellowship at the combined Dana-Farber Cancer Instute/Brigham and Women’s Hospital/Massachuses General Hospital program.

KENNETH GROSSMAN, MD, PHD Dr. Kenneth Grossmann, MD, PhD, is an associate professor in the Division of Oncology for the Department of Medicine and a Huntsman Cancer Instute invesgator. He also works at intermountain healthcare, and is building a collaborave program between these two instuons which is designed to encompass melanoma care for the state of Utah.

CureMelanoma.org 1 of 5 Addionally, he is the chair of the SWOG melanoma commiee and oversees the porolio of melanoma and cutaneous cancers research within that program.

Grossmann completed undergraduate studies in biology at Whitman College in Walla Walla, Washington. He earned his PhD and MD degrees from the Department of Molecular and Medical Genecs at Oregon Health & Sciences University (OHSU) in Portland. He completed a combined fellowship in medical oncology at OHSU and the University of Utah, and also parcipated in a melanoma and cutaneous oncology rotaon at MD Anderson Cancer Center. He has worked in the Moffit Cancer Center’s cutaneous oncology program, and connues collaboraons with mulple centers around the country.

RIZWAN HAQ, MD, PHD: Dr. Rizwan Haq is a graduate of the University of Toronto, where he completed his B.Sc. (Hon), and MD/PhD. His PhD was at the Ontario Cancer Instute/Princess Margaret Hospital in the laboratory of Dr Brent Zanke. He completed his clinical training in internal medicine at The Johns Hopkins Hospital in Balmore, followed by medical oncology training at Dana-Farber Cancer Instute and Massachuses General Hospital. He joined the laboratory of Dr David E. Fisher, where he conducted translaonal work in the melanoma; and was an aending oncologist at Massachuses General Hospital.

He was recruited back to Dana-Farber Cancer Instute in 2014. His research focuses on resistance to melanoma therapies, including targeted agents and immunotherapies. He has been a contribung author of numerous high profile publicaons, including those published in Cancer Cell, Nature, Proceedings of the Naonal Academy of Sciences USA. At Dana-Farber Cancer Instute, Dr. Haq devotes part of his me to developing the next generaon of melanoma therapeucs and translang them to innovave invesgator-iniated clinical trials. His clinical pracce is dedicated to paents with melanoma.

MICHAEL KAPLAN Michael Kaplan joined the Melanoma Research Alliance as President & CEO in 2016. Building on more than 25 years of execuve non-profit and public health leadership experience, Mr. Kaplan has a proven record as a passionate supporter of health research and policy. Mr. Kaplan is responsible for strategic direcon, overall management and raising capital to achieve MRA’s mission of ending suffering and death due to melanoma and to foster collaboraon with all stakeholders to accelerate powerful research, advance cures, and prevent more melanomas.

Mr. Kaplan has headed nonprofits and paent advocacy groups across the United States and internaonally. He has managed internaonal and domesc grant-making porolios focused on disease surveillance, prevenon and treatment. Prior to joining MRA, he served as the President and CEO of

CureMelanoma.org 2 of 5 Washington, DC-based AIDS United. Addional leadership posions have included Execuve Director of Cascade AIDS Project in Portland, Ore., Vice President at the Academy for Educaonal Development, and Deputy Director roles at both the Futures Group Internaonal and the Naonal Youth Advocacy Coalion in Washington, DC. He has served on the boards of several organizaons focusing on everything from health issues to grant-making, and behavior health to healthy youth development.

JASON LUKE, MD: Jason J. Luke, M.D., F.A.C.P. is an Associate Professor of Medicine at the University of Pisburgh Medical Center and Hillman Cancer Center where he is the Director of the Cancer Immunotherapeucs Center. Dr. Luke specializes in the management of paents with melanoma and early phase drug development (parcularly novel immunotherapeucs and biomarkers of immunotherapy acvity). Dr. Luke has been a lead naonal invesgator on clinical trials of immunotherapy agents including but not limited to an-PD1/L1, CTLA4, LAG3, TIM3, GITR, OX40, CD137, CD40, inhibitors of indolamine-dioxygenase (IDO), adenosine A2a receptor and arginase as well as agonists of STING and oncolyc virus. Dr. Luke’s major research translaonal research is focused on using large scale informacs to advance the field of cancer immunotherapy. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued internship and residency at the Boston University Medical Center followed by medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Keering Cancer Center in New York City. Following fellowship, Dr. Luke was a tenure-track, Type 1 Instructor in Medicine at Harvard Medical School as well as Staff Physician at the Dana-Farber Cancer Instute and Brigham and Women’s Hospital in Boston. Thereaer Dr. Luke was an Assistant Professor at the University of Chicago. Dr. Luke is acvely involved in several professional sociees including the Society for Melanoma Research, the Society for Immunotherapy of Cancer, American Associaon for Cancer Research and the American Society for Clinical Oncology (ASCO). Dr. Luke has served as the chair of the educaon commiee and as a member of the scienfic commiee for the melanoma track of the ASCO annual meeng. Dr. Luke has received several awards for research and clinical care including the Melanoma Research Foundaon Humanitarian Award, Crain’s 40 under 40, Department of Defense Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Invesgator Awards from the Melanoma Research Alliance, the Cancer Research Foundaon and the Conquer Cancer Foundaon of ASCO. Dr. Luke’s research has been supported by ASCO, the Naonal Comprehensive Cancer Network and the Naonal Cancer Instute.

JAMES MOON, MD: Dr. James Moon is the John Gideon Searle Associate Professor in the Department of Pharmaceucal Sciences and Biomedical Engineering at University of Michigan, Ann Arbor. He is also a member of the University of Michigan Comprehensive Cancer Center. His translaonal research program aims to improve vaccines and immunotherapies. He has received numerous awards, including 2017 Emerald

CureMelanoma.org 3 of 5 Foundaon Disnguished Invesgator Award, 2016 NSF CAREER Award, and 2016 DOD Career Development Award. Dr. Moon received his bachelor’s degree from the University of California, Berkeley, and his Ph.D. from Rice University, and he completed his postdoctoral training at MIT.

MARLANA ORLOFF, MD Dr. Marlana Orloff is an assistant professor of medicine and medical oncologist at Thomas Jefferson University Hospital – Sidney Kimmel Cancer Center in Philadelphia, PA. Her clinical and research focus is on primary and advanced melanomas. Though she sees paents with cutaneous melanoma, her main interest is in rare melanomas including uveal, conjuncval, and mucosal melanoma. Her research is centered on invesgang the epidemiology of uveal melanoma and discovery of novel therapies for primary and advanced uveal, conjuncval, mucosal and cutaneous melanoma. She works very closely with the team at Wills Eye Hospital to manage hundreds of paents with primary and advanced ocular melanomas. In addion, she currently oversees the inpaent metastac uveal melanoma service at Thomas Jefferson University Hospital that admits and treats paents with metastac uveal melanoma from all over the country. Along with medical oncologist Dr. Takami Sato, a dedicated team of intervenonal radiologists, and numerous other essenal personnel the program now performs close to 700 liver directed procedures for this disease annually. She is principal and co-invesgator on a number of clinical trials enrolling paents with primary and advanced melanomas of all types.

Her current research is funded by Melanoma Research Alliance, industry support, and the generous philanthropic support of paents and their families.

ELIZABETH ‘LIZ’ PATTON, PHD Liz Paon is a Professor and MRC Programme Leader Scienst at the MRC Human Genecs Unit, University of Edinburgh, UK. Professor Paon received a BSc Honours degree from King’s College at Dalhousie University, and a PhD from the University of Toronto, working with Mike Tyers to discover how E3 ubiquin ligases control cell division. Following this, Liz received a Human Froner Science Programme Postdoctoral Fellowship to work with Len Zon at Harvard Medical School, where she developed a zebrafish model for melanoma now used worldwide in melanoma research. Her lab uses chemical genec approaches in zebrafish to discover new drug targets and drug-leads in melanoma biology . Professor Paon is an Editor at Disease Models and Mechanisms (Company of Biologists) and Pigment Cell and Melanoma Research (Wiley). Professor Paon was the founding President of the Zebrafish Disease Models Society (2013-2015) and currently serves as a Treasurer and Board member, and is an elected member of the Young Academy of Scotland at the Royal Society of Edinburgh. Professor Paon’s research is funded by the Medical Research Council and the European Research Council, and she has been funded by a L’Oréal Paris USA–MRA Team Science Award for Women in Scienfic Research.

CureMelanoma.org 4 of 5 ANTONI RIBAS, MD, PHD Antoni Ribas, MD, PhD is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Commiee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. Dr Ribas is a physician-scienst who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adopve cell transfer (ACT) therapies, an-CTLA4 anbodies, an-PD-1 anbodies, and BRAF and MEK inhibitors.

His NCI, State of California and private foundaon-supported research laboratory develops models of disease to test new therapeuc opons and studies mechanism of acon of treatments in paents. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimenib (Cotellic), dabrafenib (Tafinlar) and tramenib (Mekinist). He is the recipient of the AACR Richard and Hinda Rosenthal Award, the AACR Lloyd J. Old Award in Cancer Immunology and a Naonal Cancer Instute (NCI) Outstanding Invesgator Award, and is the President-elect of the American Associaon for Cancer Research (AACR).

LIZ SZABO Liz Szabo, a senior correspondent and enterprise reporter who focuses on the quality of paent care, has covered medicine for two decades. Her stories about cancer and overtreatment for KHN have won numerous awards, including first place from the Naonal Headliner Awards. She also was a finalist for the Gerald Loeb and NIHCM awards. Before coming to KHN, Szabo covered medicine for USA TODAY for nearly 13 years. Her coverage of mental health and the link between poor health and substandard housing helped her earn the Victor Cohn Prize for Excellence in Medical Science Reporng in 2016. Her invesgaon of dangerous doctors, wrien while working at The Virginian-Pilot in Norfolk, Va. in 2002, won two Naonal Press Club awards and led Virginia lawmakers to toughen state laws for disciplining physicians.

CureMelanoma.org 5 of 5